Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × pelcitoclax × Sarcoma × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡